Medicine & Life Sciences
tolfenamic acid
100%
Kidney
92%
Neoplasms
81%
Transplants
65%
Acute Kidney Injury
53%
Immunotherapy
49%
Survival
43%
Hematopoietic Stem Cell Transplantation
40%
BK Virus
36%
Therapeutics
32%
Pancreatic Neoplasms
32%
Liver Transplantation
31%
Transplant Recipients
31%
Interstitial Nephritis
30%
Critical Illness
30%
Allogeneic Cells
29%
Nephrology
27%
Stem Cells
26%
Stem Cell Transplantation
25%
Renal Cell Carcinoma
25%
INCB018424
25%
Acute Tubulointerstitial Nephritis
24%
Chronic Renal Insufficiency
23%
Glomerulonephritis
22%
Kidney Diseases
22%
Membranous Glomerulonephritis
22%
Graft Rejection
21%
Nephritis
20%
Graft vs Host Disease
20%
Primary Myelofibrosis
20%
Cystitis
20%
Rituximab
19%
Melanoma
19%
Neoadjuvant Therapy
19%
Infliximab
18%
Organ Transplantation
18%
Electrolytes
18%
Hematopoietic Stem Cells
18%
Cholangiocarcinoma
18%
methyl 2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate
18%
gemcitabine
18%
Multiple Myeloma
17%
Preexisting Condition Coverage
17%
Thrombotic Microangiopathies
16%
Multicenter Studies
16%
Cytoplasmic and Nuclear Receptors
16%
Survivin
16%
Urinary Tract
16%
Growth
15%
Incidence
15%